Optimal treatment intensification for glycaemic control in patients with type 2 diabetes on two oral agents: real world comparison of GLP-1, OADs and insulin

被引：0
|
作者：
Desouza, C. [1 ]
Kirk, A. Ross [2 ]
Mangla, K. Kant [3 ]
Wolden, M. Lyng [2 ]
Lingvay, I. [4 ]
机构：
[1] Univ Nebraska Med Ctr, Omaha, NE USA
[2] Novo Nordisk AS, Soborg, Denmark
[3] Novo Nordisk Serv Ctr India Pvt Ltd, Bangalore, Karnataka, India
[4] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
596
引用
收藏
页码：S286 / S287
页数：2
相关论文
共 50 条
  • [31] Ensuring safe use of oral hypoglycaemic agents and GLP-1 agonists in people with type 2 diabetes
    Papanikolaou, N.
    Srinivas-Shankar, U.
    DIABETIC MEDICINE, 2020, 37 : 165 - 166
  • [32] Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
    Chen-Yi Yang
    Ying-Ren Chen
    Huang-Tz Ou
    Shihchen Kuo
    Cardiovascular Diabetology, 20
  • [33] Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
    Yang, Chen-Yi
    Chen, Ying-Ren
    Ou, Huang-Tz
    Kuo, Shihchen
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [34] Time to treatment intensification with GLP-1 receptor agonists for patients with type 2 diabetes in the UK: medical record review study
    Norrbacka, K.
    Stein, D.
    Matza, L. S.
    Jordan, J. B.
    Garcia-Perez, L. -E.
    Hassan, S. W.
    Boye, K. S.
    DIABETOLOGIA, 2018, 61 : S363 - S364
  • [35] Switching to insulin degludec (IDeg) improves glycaemic control in patients with Type 2 diabetes in a real-world setting
    Feher, M.
    Tentolouris, N.
    Knudsen, S.
    Lapolla, A.
    Prager, R.
    Phan, T. M.
    Wolden, M. L.
    Schultes, B.
    DIABETIC MEDICINE, 2018, 35 : 203 - 203
  • [36] NUTRITIONAL INSULIN OR GLP-1 RECEPTOR AGONIST: CROSSROADS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
    Garg, Rajesh
    ENDOCRINE PRACTICE, 2017, 23 (11) : 1357 - 1358
  • [37] Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes
    Nauck, M. A.
    Hompesch, M.
    Filipczak, R.
    Le, T. D. T.
    Zdravkovic, M.
    Gumprecht, J.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2006, 114 (08) : 417 - 423
  • [38] Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies
    Gian Paolo Fadini
    Olga Disoteo
    Riccardo Candido
    Paolo Di Bartolo
    Luigi Laviola
    Agostino Consoli
    Diabetes Therapy, 2021, 12 : 781 - 800
  • [39] Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies
    Fadini, Gian Paolo
    Disoteo, Olga
    Candido, Riccardo
    Di Bartolo, Paolo
    Laviola, Luigi
    Consoli, Agostino
    DIABETES THERAPY, 2021, 12 (03) : 781 - 800
  • [40] Oral Semaglutide: A New GLP-1 Receptor Agonist Product for the Treatment of Type 2 Diabetes
    Smith, Connor K.
    Neumiller, Joshua J.
    US PHARMACIST, 2019, 44 (10) : 36 - 45
12345